ENDPOINTS – Page 12 – Endpoints News

about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Cerevance's $47M raise; Parexel's AI pact

Last year

Centessa's public offering; Vivoryon ends Ph2 Alzheimer’s trial

Last year

Shimadzu Corporation establishes three R&D centers in the US in anticipation of business expansion for pharmaceutical ...

Last year

Nikkei Biotechnology

GNI Group to form $100M fund with Chinese state-owned enterprises

Last year

Nikkei Biotechnology

Brise raises $20M; Taro shareholder criticizes Sun Pharma deal

Last year

Ipsen, Skyhawk ink deal worth up to $1.8B; Hepion to wind down NASH trial

Last year

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

Last year

Biohaven’s $230M offering; Plus, three new PIPEs

Last year

Intra-Cellular aims to raise $500M; Lilly’s Prevail cuts three partnered programs

Last year

Takeda’s new deal with Kumquat; IL-2 biotech raises $55M

Last year

Mustang Bio to lay off workers; MaaT's new data for microbiome therapy

Last year

Japanese pharmaceutical regulations under review to resolve drug shortages and ensure stable supply

Last year

Nikkei Biotechnology

Nurix's $175M offering; Invivyd CEO is out

Last year

Century Therapeutics buys Clade; Eliem announces $120M PIPE and a deal

Last year

Skye Bioscience uplists; OncoX's licensing deal with ABVC BioPharma

Last year

Acrivon draws in $130M; Vincerx Pharma's Ph1 metastatic tumor data

Last year

LIB details Ph3 PCSK9 inhibitor data; Eyenovia seeks 'strategic alternatives'

Last year

Protara's $45M placement; Plus, news about Eupraxia and GenSight

Last year

Ascletis Pharma scraps liver disease program; Another reverse merger

Last year

Zymeworks removes CFO; Gilead extends Nurix deal

Last year

Bayer to cut 90 workers; Avalo's up to $185M private placement

Last year

Gamida Cell to go private; Stoke aims to raise $75M

Last year

Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year

Last year

Axsome clears Phase 3 in narcolepsy; Nkarta eyes $240M raise

Last year

First page Previous page 9 10 111213 14 15 Next page Last page